BSECompany Update▲ PositiveExpansion21h ago
Zydus Lifesciences Ltd
Zydus receives approval for Phase III trial of Desidustat in patients with Sickle Cell Disease, to be conducted in collaboration with ICMR.
Zydus Lifesciences Ltd has received approval for Phase III trial of Desidustat in patients with Sickle Cell Disease, to be conducted in collaboration with ICMR. The trial will evaluate the efficacy and safety of Desidustat oral tablets in treating anemia. The US FDA has granted Orphan Drug Designation (ODD) to Zydus' Desidustat for treating two rare blood disorders: Sickle Cell Disease (SCD) and beta-thalassemia.
Read more →📎 1 attachment